FOLD up +15.11% percent Today $FOLD High is at 6.70 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2014 at 12:02 PM

FOLD up +15.11% percent Today $FOLD High is at 6.70 and the Low 6.24 with current volume of 1,624,697.

Recent News posted below.

Amicus Therapeutics FOLD other info.
http://investorshangout.com/Amicus-Therapeutics-FOLD-54154/

FOLD Amicus Therapeutics Recent Headline News

Amicus Therapeutics (FOLD) Stock Surges Following Fabry Treatment Pill Results
at The Street - 34 mins ago
Shares of Amicus Therapeutics (FOLD) rose in morning trading Monday after the company announced positive results of its experimental pill migalastat in patients with Fabry disease.
FOLD: 6.58 (+0.89)

Amicus Therapeutics (FOLD) Strong On High Relative Volume Today
at The Street - 1 hr 59 mins ago
Trade-Ideas LLC identified Amicus Therapeutics (FOLD) as a strong on high relative volume candidate
FOLD: 6.58 (+0.89)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - 2 hrs 46 mins ago

CADC: 5.88 (+1.62), INO: 10.12 (-0.88), CLDX: 18.30 (+4.14), HAL: 50.01 (-5.07), ROX: 1.84 (-0.14), SNSS: 2.35 (+0.68), DNR: 9.90 (-1.30), DWA: 22.17 (-3.85), GSAT: 2.83 (-0.14), CMGE: 26.18 (+0.58), FOLD: 6.58 (+0.89), BHI: 66.03 (+6.14)

Amicus Therapeutics' Fabry disease drug candidate improves cardiac health marker
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 6:31AM CST

SHPG: 204.80 (+2.18), SNY: 47.43 (+0.75), FOLD: 6.58 (+0.89)

Amicus Drug Improves Marker of Heart Health in Fabry Patients
at The Street - Sat Nov 15, 9:01AM CST
The new migalastat data compliment earlier esults from successful phase III study announced in August by Amicus.
SHPG: 204.80 (+2.18), SNY: 47.43 (+0.75), FOLD: 6.58 (+0.89)

Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac and Composite Endpoints from Fabry Monotherapy Study 012 at American Society of Nephrology
GlobeNewswire - Sat Nov 15, 9:00AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced additional positive data on important secondary endpoints from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl ("migalastat"

for Fabry disease. In a poster at the American Society of Nephrology (ASN) Kidney Week 2014, results were presented from Fabry patients with amenable mutations in Study 012 who switched from standard of care enzyme replacement therapy (ERT) to migalastat as their only therapy for Fabry disease. A slide presentation featuring these data is also available at http://ir.amicustherapeutics.com/events.cfm.
FOLD: 6.58 (+0.89)

Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Pipeline Review H2 2014 - Analysis of 9 Companies & 12 Drug Profiles
M2 - Tue Nov 11, 5:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/hphx7p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Athersys, Inc. - OPKO Health, Inc. - Amicus Therapeutics, Inc. - ReGenX Biosciences, LLC - AngioChem Inc. - PTC Therapeutics, Inc. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - ataluren - FT-1050 - MultiStem - AGT-181 - Gene Therapy to Activate Iduronidase for Hurler Syndrome - Oligonucleotide for Mucopolysaccharidosis I - (laronidase Chaperone) - Recombinant Enzyme for Hurler Syndrome - Stem Cell Therapy for Type1 Mucopolysaccharidosis - Cell Therapy for Mucopolysaccharidosis I - Cell Therapy to Activate Iduronidase for Hurler Syndrome - Recombinant Enzyme to Activate Alpha-L-Iduronidase for Mucopolysaccharidosis I For more information visit http://www.researchandmarkets.com/research/hp...saccharido
FATE: 3.59 (-0.37), OPK: 8.26 (-0.03), PTCT: 39.36 (+0.47), ATHX: 1.36 (-0.01), FOLD: 6.58 (+0.89)

Amicus Therapeutics' (FOLD) CEO John Crowley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 09, 8:50AM CST

FOLD: 6.58 (+0.89)

Amicus Therapeutics posts 3Q loss
Automated Insights - Thu Nov 06, 5:30PM CST
CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $17.1 million, or 22 cents per share, in its third quarter.
FOLD: 6.58 (+0.89)

Amicus Therapeutics misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:13PM CST

FOLD: 6.58 (+0.89)

Amicus Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Updates
GlobeNewswire - Thu Nov 06, 3:01PM CST
Important New Migalastat Data on Cardiac and Other Key Secondary Endpoints for Study 012 to be Presented At American Society of Nephrology Meeting on November 15
FOLD: 6.58 (+0.89)

Amicus reports November 6
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 10:10AM CST

FOLD: 6.58 (+0.89)

Amicus Therapeutics Announces Timing of Third Quarter 2014 Financial Results, Upcoming Scientific Conference and Other Corporate Updates
GlobeNewswire - Mon Nov 03, 7:37AM CST
Amicus Therapeutics (Nasdaq:FOLD) today announced that a conference call and live audio webcast are scheduled for Thursday, November 6, 2014 at 5:00 p.m. ET to discuss financial results for the third quarter ended September 30, 2014.
FOLD: 6.58 (+0.89)

InsiderInsights.com Daily Round Up 10/28/14: POL, NHF, SLB, ATI
InsiderInsights - at Seeking Alpha - Wed Oct 29, 5:58AM CDT

CLUB: 5.64 (-0.02), GD: 142.32 (-0.34), ATI: 32.31 (-0.54), CACC: 159.66 (-0.90), HSON: 3.18 (-0.19), AAMC: 480.10 (-0.90), BMY: 58.13 (+0.18), SLB: 95.66 (+0.34), MXWL: 10.71 (-0.49), POL: 36.77 (+0.09), BTU: 11.30 (-0.09), NOW: 64.96 (-2.55), OMAM: 15.77 (+0.20), TYL: 110.00 (-0.46), NHF: 11.30 (+0.12), FBC: 15.46 (-0.26), ACN: 84.48 (-0.16), FOLD: 6.58 (+0.89), SWHC: 9.55 (-0.10)

Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma
PR Newswire - Wed Oct 22, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Amicus Therapeutics Inc. (NASDAQ: FOLD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), and Merrimack Pharmaceuticals Inc. (NASDAQ: MACK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 21, 2014, the NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow Jones Industrial Average advanced 1.31%, to finish the day at 16,614.81, and the S&P 500 closed at 1,941.28, up 1.96%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.36, up 2.65%, with the index also advancing 5.56% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
MACK: 8.70 (+0.22), PGNX: 6.47 (+0.14), IDRA: 2.40 (-0.05), THLD: 2.93 (+0.06), FOLD: 6.58 (+0.89)

Amicus Reports Additional Positive Data on Fabry Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 5:35PM CDT
Amicus Therapeutics, Inc. (FOLD) announced additional positive data from a phase III study (Study 011) on migalastat, for treating Fabry disease patients.
HALO: 8.62 (+0.08), EBS: 24.41 (+0.19), SNY: 47.43 (+0.75), FOLD: 6.58 (+0.89)

Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT

BIIB: 305.18 (-0.25), MNOV: 3.03 (-0.04), CHTP: 6.52 (-0.03), ADMS: 14.56 (-0.27), ACOR: 34.08 (+0.61), BCLI: 3.37 (-0.10), BSX: 13.39 (+0.03), IPXL: 28.83 (-0.03), AVNR: 13.25 (+0.12), ACAD: 27.27 (+0.13), CVTS: (), MRK: 59.54 (+0.47), TEVA: 57.60 (+0.53), PRTA: 22.02 (+0.49), PRAN: 1.70 (-0.03), FOLD: 6.58 (+0.89), CUR: 2.85 (-0.01)

Amicus Therapeutics Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011
GlobeNewswire - Sun Oct 19, 6:00PM CDT
Across All Subgroups, Patients Treated with Migalastat Compare Favorably to Natural History on Kidney Function (eGFR)
FOLD: 6.58 (+0.89)

Amicus Therapeutics to Present at Leerink Partners Rare Disease Roundtable
GlobeNewswire - Tue Sep 30, 8:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD) today announced that Bradley Campbell, Chief Operating Officer and Chip Baird, Chief Financial Officer, will present a corporate overview at the Leerink Partners Rare Disease Roundtable in New York, NY on Wednesday, October 1, 2014 at 8:50 a.m. ET.
FOLD: 6.58 (+0.89)

Amicus Therapeutics Inc. (FOLD) Stock Research Links

FOLD Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navigating the Nitty-Gritty of Cabin Rental Management

The Real Elbow Grease Behind Cabin Management Ever imagined what it’d take to keep a vacation rental cabin running like a tight ship? Well, Nathan Fitts breaks it down real clear-like. The guy's seen it all in Blue Ridge, Georgia, which isn't just about scenic views—there's serious business brewing behind that cabin charm. More Than Just Fluffing Pillows Turns out,...

VIVIFY and ELISIUM Plan Hydrogen-Powered City

Hydrogen Takes Center Stage in Urban Planning Well, I didn't see this one coming—a city that's planning the power before the buildings. We're talking about ELISIUM, the so-called cognitive city destined to rise in Hendry County, Florida. And leading the charge in all this energy planning? None other than VIVIFY Technology, set to bring in its hydrogen expertise right...

TilePix Expands into Walmart with Nail-Free Decor Launch

TilePix Makes Big Moves with Walmart TilePix is launching their new line of nail-free wall décor at Walmart—this ain’t your grandma’s wall art. This company's bringing their magnetic, nail-free wizardry to retail stores nationwide for the first time, and they’ve chosen a real heavyweight partner—Walmart. What comes in the package? Well, they’re dealing in...

Brown Plus Ranks #8 Best Workplace for Women 2026

Cracking the Top Ten: A Noteworthy Feat When it comes to hustling and bustling in the corporate world, Brown Plus managed to snag the spotlight by landing the #8 spot in the 'Best Place to Work for Women 2026.' It's a title they didn't just stumble upon. This recognition in the medium category by the Best Companies Group underscores the fact that Brown Plus is running its...

Coastal Financial Faces Lawsuit Over Fraud Allegations

Coastal Financial Corporation, riding high on NASDAQ as CCB, now finds itself in the middle of a storm. Schall, Brown & Schwartz LLP, a firm known for its shareholder rights litigation, has thrown the gauntlet with a class action lawsuit against Coastal for suspected securities violations. We're talking about potential fibs under Section 10(b) and 20(a) of the Securities...

Noé Hinojosa Jr. Honored for Leadership in Business

From Bonds to Ballgames: Hinojosa's Impact Listen up, because this one’s more than just another accolade on a shelf. Noé Hinojosa Jr., a big gun over at TRB Securities, is getting the 2026 Hispanic Business Salute Award, and it's a doozy. Awarded by all the big wigs—UPS, NBC 5, Telemundo 39, and the Dallas Cowboys—this isn't a small pat on the back. It's a full-on...

Chemours Faces Investor Fraud Suit: Action Needed Now

A Messy Situation Unfolds for Chemours Company You know, stumbling upon a battle scene like this isn't something I enjoy, but here we have Chemours Company (NYSE: CC) embroiled in a securities fraud lawsuit. It's like catching wind of a brawl outside your favorite tavern—can't ignore it, can you? The Lawsuit's Crux and Key Dates to Watch Here's the rundown. The fight...

Taiwan Excellence Sparks Smart Automotive Innovation at SEMA

Taiwan's making waves, folks, and it's not your everyday splash in the automotive pool. At SEMA 2026, Taiwan Excellence Pavilion is the place to be with its array of intelligent automotive solutions. This ain't just your run-of-the-mill car show gimmickry—it's the future rolling in real-time. Driving Innovation: From Components to Smart Systems The name of the game is...

Ruth E. Carter Returns Home with Celebrated Exhibition

Ruth E. Carter’s Triumphant Return When a titan of the costume design world circles back to their roots, you know it’s bound to be something special. Ruth E. Carter, who has swapped needles and threads for Oscars (twice, mind you), is making a return to Hampton University, paying homage to the very soil that sowed her artistic seeds. Ain't that a capstone of a career...

Cruise Planners Sets AI Benchmark in Travel Innovs

Unveiling the AI Arsenal of Cruise Planners Alright, listen up, folks. When you think about travel and tech, Cruise Planners ain't just dipping a toe—they're cannonballing right in, splashing everyone around with their shiny new AI tricks. Twenty-three. That's how many innovations they're flaunting this year. It's like they're running a tech marathon, and boy, are they...